Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI Atai Life Sciences	$1.50 +6.4%	$1.45	$1.03 ▼ $2.57	$299.69M	1.24	1.50 million shs	1.92 million shs
ATYR Atyr PHARMA	$3.47 +2.7%	$3.31	$1.42 ▼ $4.66	$308.34M	0.95	902,416 shs	744,976 shs
PROK ProKidney	$0.89 -18.0%	$0.92	$0.46 ▼ $4.44	$259.21M	1.52	683,078 shs	1.09 million shs
STRO Sutro Biopharma	$1.05 +20.0%	$0.93	$0.52 ▼ $5.17	$88.58M	1.7	1.07 million shs	2.93 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI Atai Life Sciences	-3.42%	-4.08%	-4.08%	-6.00%	-28.43%
ATYR Atyr PHARMA	+3.36%	-2.59%	+7.99%	-6.89%	+337,999,900.00%
PROK ProKidney	+4.85%	+44.17%	+18.68%	-32.50%	-53.04%
STRO Sutro Biopharma	-2.46%	+20.68%	+18.67%	-53.47%	-75.15%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATAI Atai Life Sciences	2.6737 of 5 stars	3.5	1.0	0.0	3.3	3.3	0.6
ATYR Atyr PHARMA	2.3984 of 5 stars	3.6	1.0	0.0	2.1	3.3	0.6
PROK ProKidney	2.4901 of 5 stars	3.3	0.0	0.0	3.6	4.2	0.6
STRO Sutro Biopharma	4.3687 of 5 stars	4.1	2.0	4.7	3.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI Atai Life Sciences	3.00	Buy	$10.50	600.00% Upside
ATYR Atyr PHARMA	3.14	Buy	$18.60	436.02% Upside
PROK ProKidney	2.50	Moderate Buy	$5.00	464.59% Upside
STRO Sutro Biopharma	2.22	Hold	$6.63	530.95% Upside

Current Analyst Ratings Breakdown

Latest STRO, PROK, ATAI, and ATYR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/29/2025	STRO Sutro Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$2.00 ➝ $2.00
3/19/2025	ATAI Atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/17/2025	STRO Sutro Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$12.00 ➝ $2.00
3/14/2025	STRO Sutro Biopharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$2.00
3/14/2025	ATYR Atyr PHARMA	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00 ➝ $35.00
3/14/2025	STRO Sutro Biopharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
3/14/2025	STRO Sutro Biopharma	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
3/14/2025	STRO Sutro Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$8.00 ➝ $2.00
3/14/2025	STRO Sutro Biopharma	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Underperform	$11.00 ➝ $1.00
2/18/2025	ATYR Atyr PHARMA	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
2/18/2025	ATYR Atyr PHARMA	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$16.00

(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI Atai Life Sciences	$308K	973.03	N/A	N/A	$1.47 per share	1.02
ATYR Atyr PHARMA	$235K	1,312.09	N/A	N/A	$1.54 per share	2.25
PROK ProKidney	$76K	3,410.70	N/A	N/A	($4.84) per share	-0.18
STRO Sutro Biopharma	$62.04M	1.43	N/A	N/A	$2.45 per share	0.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI Atai Life Sciences	-$40.22M	-$0.93	N/A	N/A	N/A	N/A	-65.75%	-52.71%	5/13/2025 (Estimated)
ATYR Atyr PHARMA	-$50.39M	-$0.87	N/A	N/A	N/A	N/A	-79.44%	-59.16%	5/1/2025 (Estimated)
PROK ProKidney	-$35.47M	-$0.63	N/A	N/A	N/A	N/A	N/A	-10.24%	5/9/2025 (Estimated)
STRO Sutro Biopharma	-$106.79M	-$3.02	N/A	N/A	N/A	-77.01%	-101.89%	-28.69%	5/12/2025 (Estimated)

Latest STRO, PROK, ATAI, and ATYR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	ATAI Atai Life Sciences	-$0.19	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	STRO Sutro Biopharma	-$0.63	N/A	N/A	N/A	$11.61 million	N/A
5/9/2025	Q1 2025	PROK ProKidney	-$0.16	N/A	N/A	N/A	N/A	N/A
5/1/2025	Q1 2025	ATYR Atyr PHARMA	-$0.19	N/A	N/A	N/A	N/A	N/A
3/17/2025	Q4 2024	ATAI Atai Life Sciences	-$0.14	-$0.24	-$0.10	-$0.24	$0.30 million	($0.01) million
3/17/2025	Q4 2024	PROK ProKidney	-$0.14	-$0.17	-$0.03	-$0.17	N/A	$0.08 million
3/13/2025	Q4 2024	ATYR Atyr PHARMA	-$0.23	-$0.18	+$0.05	-$0.18	$0.02 million	N/A
3/13/2025	Q4 2024	STRO Sutro Biopharma	-$0.86	-$2.96	-$2.10	-$0.89	$10.44 million	$14.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI Atai Life Sciences	N/A	N/A	N/A	N/A	N/A
ATYR Atyr PHARMA	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A
STRO Sutro Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI Atai Life Sciences	0.14	5.81	5.81
ATYR Atyr PHARMA	0.02	5.41	5.41
PROK ProKidney	N/A	17.08	17.09
STRO Sutro Biopharma	N/A	3.09	3.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI Atai Life Sciences	28.41%
ATYR Atyr PHARMA	61.72%
PROK ProKidney	51.59%
STRO Sutro Biopharma	96.99%

Insider Ownership

Company	Insider Ownership
ATAI Atai Life Sciences	31.20%
ATYR Atyr PHARMA	3.70%
PROK ProKidney	41.49%
STRO Sutro Biopharma	5.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI Atai Life Sciences	80	199.80 million	115.45 million	Optionable
ATYR Atyr PHARMA	53	88.86 million	80.84 million	Optionable
PROK ProKidney	3	292.70 million	170.65 million	Optionable
STRO Sutro Biopharma	240	84.36 million	77.59 million	Optionable

STRO, PROK, ATAI, and ATYR Headlines

Recent News About These Companies

Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of "Hold" from Analysts

April 28 at 2:24 AM | marketbeat.com

Sutro Biopharma, Inc. (NASDAQ:STRO) Given Consensus Recommendation of "Hold" by Brokerages

April 27 at 2:24 AM | americanbankingnews.com

Why Sutro Biopharma, Inc.’s (STRO) Stock Is Down 21.92%

April 26, 2025 | aaii.com

Contrasting Bio-Techne (NASDAQ:TECH) and Sutro Biopharma (NASDAQ:STRO)

April 26, 2025 | americanbankingnews.com

Why Sutro Biopharma, Inc.’s (STRO) Stock Is Down 10.88%

April 1, 2025 | aaii.com

Why Sutro Biopharma, Inc.’s (STRO) Stock Is Up 15.10%

March 18, 2025 | aaii.com

Sutro Biopharma downgraded to Neutral from Buy at H.C. Wainwright

March 17, 2025 | markets.businessinsider.com

HC Wainwright & Co. Downgrades Sutro Biopharma (STRO)

March 17, 2025 | msn.com

Sutro Biopharma presents expanded data from REFRalphaME-01 trial

March 17, 2025 | markets.businessinsider.com

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

March 15, 2025 | tmcnet.com

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRaME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

March 15, 2025 | tmcnet.com

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

March 15, 2025 | globenewswire.com

Why Sutro Biopharma, Inc.’s (STRO) Stock Is Down 35.19%

March 15, 2025 | aaii.com

Wedbush Downgrades Sutro Biopharma (STRO)

March 15, 2025 | msn.com

Sutro Biopharma downgraded to Neutral from Overweight at Piper Sandler

March 14, 2025 | markets.businessinsider.com

Sutro Cuts Half of Staff, Deprioritizes ADC in Strategic Review

March 14, 2025 | biospace.com

New ADC focus as Sutro slashes workforce, drops lead drug

March 14, 2025 | thepharmaletter.com

Sutro drops as portfolio review leads to downgrades

March 14, 2025 | msn.com

Sutro Biopharma, Inc.: Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

March 14, 2025 | finanznachrichten.de

Sutro Biopharma, Inc.: Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline

March 14, 2025 | finanznachrichten.de

Sutro discards CEO, 50% of staff, sole clinical-stage ADC and manufacturing site to save cash

March 14, 2025 | fiercebiotech.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

5 Hot Stock Buys for Investors in April
By Thomas Hughes | April 1, 2025
View 5 Hot Stock Buys for Investors in April
5 Reasons the S&P 500 Could Rebound Strongly in 2025
By Thomas Hughes | April 3, 2025
View 5 Reasons the S&P 500 Could Rebound Strongly in 2025
Why NVIDIA Stock Could Soar Despite Wall Street Downgrades
By Thomas Hughes | April 14, 2025
View Why NVIDIA Stock Could Soar Despite Wall Street Downgrades
PayPal Stock: Too Cheap to Ignore, Too Strong to Miss
By Jea Yu | April 8, 2025
View PayPal Stock: Too Cheap to Ignore, Too Strong to Miss
Chip Giant ASML Gets New Price Targets With Big Upside
By Leo Miller | April 24, 2025
View Chip Giant ASML Gets New Price Targets With Big Upside

STRO, PROK, ATAI, and ATYR Company Descriptions

Atai Life Sciences NASDAQ:ATAI

$1.50 +0.09 (+6.38%)

As of 04:00 PM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Atyr PHARMA NASDAQ:ATYR

$3.47 +0.09 (+2.66%)

As of 04:00 PM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

ProKidney NASDAQ:PROK

$0.89 -0.19 (-18.00%)

As of 04:00 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Sutro Biopharma NASDAQ:STRO

$1.05 +0.18 (+20.04%)

As of 04:00 PM Eastern

Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time